Single Dose Study of BMS-820836

Summary

The purpose of this study is to determine the safety and tolerability of BMS-820836 after single doses

Conditions

• Depression

Interventions

DRUG

BMS-820836

Oral Solution, Oral, 2 mg, single dose, one dose

DRUG

BMS-820836

Oral Solution, Oral, 3 mg, single dose, one dose

DRUG

BMS-820836

Oral Solution, Oral, 5 mg, single dose, one dose

DRUG

BMS-820836

Oral Solution, Oral, 8 mg, single dose, one dose

DRUG

Placebo

Oral Solution, Oral, 0 mg, single dose, one dose

DRUG

BMS-820836

Oral Solution, Oral, 3 mg, single dose, one dose

DRUG

BMS-820836

Oral Solution, Oral, 0.5 mg, single dose, one dose

DRUG

BMS-820836

Oral Solution, Oral, 0.025 mg, single dose, one dose

DRUG

BMS-820836

Oral Solution, Oral, 0.1 mg, single dose, one dose

DRUG

BMS-820836

Oral Solution, Oral, 0.25 mg, single dose, one dose

DRUG

BMS-820836

Oral Solution, Oral, 0.5 mg, single dose, one dose

DRUG

BMS-820836

Oral Solution, Oral, 1 mg, single dose, one dose

Sponsors & Collaborators

• Bristol-Myers Squibb

  lead INDUSTRY

Principal Investigators

• Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

55 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2008-07-31

Primary Completion

2009-04-30

Completion

2009-04-30

Countries

• Canada

Study Locations